Following a dip in the first-quarter operating profit announced by Takeda, which is being attributed to the loss of US exclusivity for its blockbuster cancer drug and a lacking pipeline, it may find a saving grace in its recent merger with Shire Read more


An upcoming merger agreement between Pfizer and Anacor, worth around $5.2bn, is set to boost the companies’ pipeline candidates in the atopic dermatitis space, according to GlobalData Read more


It seems we’re never far from a merger or acquisition in the pharmaceutical sector Read more


BioAlliance Pharma has received pre-approval from NASDAQ OMX Copenhagen for the secondary listing and admission to trading on NASDAQ OMX Copenhagen of the shares of BioAlliance Pharma SA. Read more